ReviewFuture oncology (London, England)2010
Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis.
Review in Future oncology (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study.Diseases of the colon and rectum · 2014Trial
- RNF114-PACSIN3 signaling axis promotes hepatocellular carcinoma progression by enhancing GLUT1 membrane retention and glucose uptake.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- E2F1-Dependent CDCA5 overexpression drives cervical cancer progression and correlates with poor prognosis.Journal of molecular histology · 2025Article
- RNF114 Interacts with EWSR1 to Regulate VEGFR2 in HER2-positive Breast Cancer.Journal of Cancer · 2025Article
- Article
- Circadian Genes MBOAT2/CDA/LPCAT2/B4GALT5 in the Metabolic Pathway Serve as New Biomarkers of PACA Prognosis and Immune Infiltration.Life (Basel, Switzerland) · 2023Article
- Targeting ESM1/ VEGFα signaling axis: a promising therapeutic avenue for angiogenesis in cervical squamous cell carcinoma.Journal of Cancer · 2023Article
- B4GALT5 high expression associated with poor prognosis of hepatocellular carcinoma.BMC cancer · 2022Article
- LncmiRHG-MIR100HG: A new budding star in cancer.Frontiers in oncology · 2022Review
- Article
- Aberrant methylation-mediated downregulation of lncRNAJournal of biological research (Thessalonike, Greece) · 2020Article
- Identification of Core Genes Involved in the Progression of Cervical Cancer Using an Integrative mRNA Analysis.International journal of molecular sciences · 2020Article
- Research progress on KIF3B and related diseases.Annals of translational medicine · 2019Review
- Identification of Significant Gene Signatures and Prognostic Biomarkers for Patients With Cervical Cancer by Integrated Bioinformatic Methods.Technology in cancer research & treatment · 2018Article
- CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Novel Somatic Copy Number Alteration Identified for Cervical Cancer in the Mexican American Population.Medical sciences (Basel, Switzerland) · 2016Article
- Article
- Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell.Molecular carcinogenesis · 2016Article
- Somatic Variations in Cervical Cancers in Indian Patients.PloS one · 2016Article
- Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma.Hepatology international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Cervical cancer (CC) as a single diagnostic entity exhibits differences in clinical behavior and poor outcomes in response to therapy in advanced tumors. Although infection of high-risk human papillomavirus is recognized as an important initiating event in cervical tumorigenesis, stratification of CC into subclasses for progression and response to treatment remains elusive. Existing knowledge of genetic, epigenetic and transcriptional alterations is inadequate in addressing the issues of diagnosis, progression and response to treatment. Recent technological advances in high-throughput genomics and the application of integrative approaches have greatly accelerated gene discovery, facilitating the identification of molecular targets. In this article, we discuss the results obtained by preliminary integrative analysis of DNA copy number increases and gene expression, utilizing the two most common copy number-gained regions of 5p and 20q in identifying gene targets in CC. These analyses provide insights into the roles of genes such as RNASEN, POLS and SKP2 on 5p, KIF3B, RALY and E2F1 at 20q11.2 and CSE1L, ZNF313 and B4GALT5 at 20q13.13. Future integrative applications using additional datasets, such as mutations, DNA methylation and clinical outcomes, will raise the promise of accomplishing the identification of biological pathways and molecular targets for therapies for patients with CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.